Trials / Completed
CompletedNCT02596074
Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
A Phase 2, Randomized, Double-Blind, Parallel-Group Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With Usual Type Vulvar Intraepithelial Neoplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Maruho Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the pharmacodynamics, safety/tolerability and efficacy of topical Omiganan (CLS001) in patients with usual type vulvar intraepithelial neoplasia (uVIN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omiganan (CLS001) topical gel | |
| DRUG | Vehicle topical gel |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2017-03-07
- Completion
- 2017-07-04
- First posted
- 2015-11-04
- Last updated
- 2017-08-03
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02596074. Inclusion in this directory is not an endorsement.